NasdaqGS:KRYSBiotechs
Does FDA RMAT Status For KB707 In Lung Cancer Change The Bull Case For Krystal Biotech (KRYS)?
In February 2026, Krystal Biotech announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, its inhaled, redosable immunotherapy for advanced or metastatic non-small cell lung cancer, based on early KYANITE-1 data showing durable responses and clinically meaningful tumor reductions.
This RMAT status gives Krystal Biotech enhanced access to FDA guidance and potential accelerated pathways, highlighting how its gene therapy platform is extending beyond...